Skip to main content
Akari Therapeutics Plc logo

Akari Therapeutics Plc — Investor Relations & Filings

Ticker · AKTX ISIN · US00972G2075 US Manufacturing
Open in API
Filings indexed 694 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country US United States of America
Listing US AKTX

About Akari Therapeutics Plc

https://www.akaritx.com/

Akari Therapeutics Plc is an innovative targeted oncology company focused on developing next-generation antibody-drug conjugates (ADCs) and utilizing a novel discovery engine. The company's platform is built around proprietary cancer-killing toxins designed for targeted delivery to tumor cells. Its lead payload is PH1, which is engineered to create potent therapies for cancer treatment.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-22 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-19 English
S-1 - Akari Therapeutics Plc (0001541157) (Filer)
Capital/Financing Update Classification · 85% confidence The document is a Form S-1 registration statement (preliminary prospectus) filed under the Securities Act of 1933, detailing the proposed sale of American Depositary Shares and associated warrants. It is a capital‐raising financing document describing the terms of the offering, use of proceeds, plan of distribution and related underwriting arrangements. This clearly is an update on the company’s financing activities (securing new equity capital) rather than an internal annual report, earnings release or board change. Accordingly, it should be classified as a Capital/Financing Update (CAP).
2026-05-08 English
10-K - Akari Therapeutics Plc (0001541157) (Filer)
Annual Report
2026-03-30 English
8-K - Akari Therapeutics Plc (0001541157) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or corporate changes. The text specifically discusses a material modification to the rights of security holders, namely a reverse stock split changing the ratio of American Depositary Shares. It includes a press release as an exhibit and is signed by the Interim CFO. There are no financial statements or detailed financial data presented, and the document is not an annual or quarterly report. This type of filing is best classified as a Capital/Financing Update (CAP) because it relates to a change in the capital structure (reverse stock split). The document length is 5555 characters, which is sufficient for a substantive filing rather than a mere announcement. Therefore, the appropriate classification is CAP with high confidence.
2026-03-17 English
8-K - AKARI THERAPEUTICS PLC (0001541157) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 2, 2026, by Akari Therapeutics, Plc. The key content is under Item 5.07, which is "Submission of Matters to a Vote of Security Holders." It details the voting results from a Special General Meeting of shareholders, including the number of shares voted for, against, abstained, and broker non-votes. The document reports final voting results on several resolutions related to exercisability of warrants and issuance of shares. This type of filing is specifically about the declaration of voting results from a shareholder meeting. It is not an annual or quarterly report, nor a proxy statement or management discussion. It is not a report publication announcement or a certification. Therefore, the most appropriate classification is "Declaration of Voting Results & Voting Rights Announcements" (DVA). The document length is 6771 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report publication. Confidence is high given the clear content and form type.
2026-03-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.